Novo Nordisk is a global healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, it researches, develops, manufactures, and markets medicines for serious chronic diseases. The company is listed on Nasdaq Copenhagen, with American Depositary Receipts traded in the U.S.
Core areas include diabetes and obesity, as well as rare endocrine and blood disorders. Its portfolio spans human and analogue insulins, GLP-1–based therapies, and other peptide and protein biologics. Novo Nordisk operates extensive bioprocessing, active pharmaceutical ingredient production, formulation, and fill–finish facilities worldwide, and collaborates with academic and industry partners on emerging modalities such as cell therapy.
Official website: novonordisk.com
chemXplore tracks active investment projects involving Novo Nordisk, across sectors such as Basic Chemicals, Biobased & Circular, and Polymers.
Novo Nordisk's role is mapped on each — as Owner.
To provide comprehensive coverage, we aggregate data and news under the name Novo Nordisk, encompassing the following company names, divisions, and related entities:
Novo and NVO.
This list encompasses current and former names, alternate names, and key divisions associated with Novo Nordisk, ensuring you can easily find all relevant information under a single, unified profile.
